# DEPDC1 facilitated malignant phenotypes and disease progression of liposarcoma by modulating KIF20A

**Authors:** Mingwei Yu, Huishan Zhao, Yujie Sun

PMC · DOI: 10.3389/fendo.2025.1591390 · 2025-06-17

## TL;DR

This study shows that DEPDC1 promotes liposarcoma progression by interacting with KIF20A and activating a key cancer-related signaling pathway.

## Contribution

The novel finding is that DEPDC1 interacts with KIF20A to drive liposarcoma malignancy via the PI3K/AKT/mTOR pathway.

## Key findings

- DEPDC1 and KIF20A are overexpressed in liposarcoma and correlate with worse patient survival.
- DEPDC1 enhances cancer cell proliferation, migration, and invasion in vitro.
- KIF20A deletion reduces DEPDC1's oncogenic effects and signaling pathway activation.

## Abstract

DEP domain containing 1 (DEPDC1) has been well-known as a significant contributor to tumorigenesis and cancer progression. However, its potential oncogenic mechanism in liposarcoma is still unclear.

In this study, the expression and clinical relevance of DEPDC1 in sarcoma was assessed by employing data from The Cancer Genome Atlas (TCGA) data and conducting Kaplan-Meier online analyses, respectively. Furthermore, the impact of DEPDC1 on cellular functions of liposarcoma cell lines and its underlying mechanisms were studied using the in vitro assays.

Here, our findings revealed that the expression levels of DEPDC1 and KIF20A were elevated in liposarcoma compared to the paired adjacent adipose tissues, with their expression positively correlating with the malignancy of liposarcoma. Moreover, patients with high DEPDC1 or KIF20A mRNA levels experienced shorter survival times. In vitro assays showed that DEPDC1 overexpression enhanced cell proliferation, migration, and invasion in 93T449 cells, whilst an opposite effect was observed in SW872 cells with DEPDC1 knockdown. Furthermore, potential interacting proteins of DEPDC1 were predicted by STRING, and the DEPDC1-KIF20A interaction was confirmed by co-immunoprecipitation in liposarcoma cells. The deletion of KIF20A partially mitigated the promoting effect of DEPDC1 on the malignant phenotype of liposarcoma cells and the activation of PI3K/AKT/mTOR signaling pathway.

In conclusion, this study suggested that DEPDC1 might interact with KIF20A to promote the occurrence and progression of liposarcoma by activating PI3K/AKT/mTOR signaling pathway.

## Linked entities

- **Genes:** DEPDC1 (DEP domain containing 1) [NCBI Gene 55635], KIF20A (kinesin family member 20A) [NCBI Gene 10112], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475]
- **Diseases:** liposarcoma (MONDO:0003585)

## Full-text entities

- **Genes:** KIF20A (kinesin family member 20A) [NCBI Gene 10112] {aka MKLP2, RAB6KIFL, RCM6}, DEPDC1 (DEP domain containing 1) [NCBI Gene 55635] {aka DEP.8, DEPDC1-V2, DEPDC1A, SDP35}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** tumorigenesis (MESH:D063646), Cancer (MESH:D009369), sarcoma (MESH:D012509), liposarcoma (MESH:D008080)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** 93T449 — Homo sapiens (Human), Atypical lipomatous tumor/well differentiated liposarcoma, Cancer cell line (CVCL_U614), SW872 — Homo sapiens (Human), Liposarcoma, Cancer cell line (CVCL_1730)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12208836/full.md

---
Source: https://tomesphere.com/paper/PMC12208836